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Abstract 
With increasing numbers of advanced therapies including cell and gene therapies entering early and 
late-stage clinical development, significant focus has been directed towards the development of 
scalable, robust manufacturing processes. Much of the research and development activity in the 
sector has addressed the upstream challenges with particular emphasis on large-scale cell expansion, 
however equally important is the development of large-scale harvesting and downstream processing 
operations. This paper presents and summarises some of the challenges associated with the 
downstream processing of these advanced therapies and highlights recent advancements in the 
technologies suitable for such applications.   
Introduction 
The unavoidable transition towards an older aging population has become a significant medical 
challenge faced by many developed and developing economies. The increased demand for hospital 
and social care coupled with complex medical interventions, has led to spiralling costs for healthcare 
systems globally. Advanced therapies, including cell and gene-based therapies (CGTs) have the 
potential to address previously unmet patient needs, improving overall healthcare costs as well as 
tackling the social and economic effects of chronic and age-related conditions. However, before this 
can be realised, it is critical that robust, scalable and cost-effective manufacturing processes, that 
retain cell functionality, are developed. Unlike traditional manufacture of monoclonal antibodies 
(mAbs) and other biologics, the production and processing of cellular material, forms the basis of the 
product for CGTs [1] . As such, manufacturing processes need to be adapted to ensure that the cellular 
material retains the critical quality attributes (CQAs) throughout the entire process [2, 3]. 
As with the production of mAbs, significant research and development for CGT processes has focused 
on the intensification of upstream processes. For example, several studies have investigated the 
optimization of cell expansion processes of adherent human cells. Significant progress has been made 
in recent years with densities for human mesenchymal stem cells (hMSCs) cultured on microcarriers 
now reaching densities of >1x106 cells mL-1 [4] and human pluripotent stem cells (hPSCs) reaching 
densities of >2-3x106 cells mL-1 [5]. Whilst R&D activity should continue focusing on improving cell 
density, the shift of the manufacturing bottlenecks is inevitably leaning towards downstream 
processing (DSP) [6]. The DSP activities for cell therapies are those unit operations and processes 
which arise post after the cellular expansion stage and, depending on the therapy, can include 
harvesting, washing, cell concentration, formulation, final fill and finish and preservation. 
Despite the fact that most CGT manufacturing processes include a clariﬁcation and concentration step 
of the cellular material derived from cell culture, DSP remains largely unaddressed. Typically, a swing-
bucket rotor centrifugation step or a filtration step is included to remove cell debris, large aggregates, 
unwanted proteins, volume reduce (concentrate) and formulate the cellular suspension into a patient-
friendly or preservation-friendly buffer [6]. In the vast majority of expansion studies, there is little or 
no mention of the harvest and subsequent DSP of the cells. For anchorage-dependent cells, 
dissociation into single-cell suspension whilst retaining the CQAs is essential. Current available DSP 
platforms generally offer either high specificity or high throughput, but rarely both. Whilst highly 
specific labelling separation systems may be suitable within low volume production (proof-of-
principle, small scale studies or autologous applications), it is extremely unlikely these will meet the 
demands in the allogeneic manufacturing environment. Equally, DSP techniques adapted from protein 
production for CGTs have the capacity to handle the scales required for allogeneic therapies but are 
hindered by the lack of specificity and sensitivity to target cell isolation. With increasing volumes, cell 
densities and more stringent target product profiles to meet regulatory requirements, the need for 
efficient, highly specific and scalable DSP techniques to effectively purify and formulate the final 
product, will be just as essential as cell expansion.  
Harvest 
The harvesting of cells is the process of removing the cells from the culture vessel (stirred-tank 
bioreactors, hollow-fibre/packed-bed reactors, gas-permeable membrane reactors, etc.) after 
expansion. Given the wide variety of CGTs, the use of both anchorage-dependent and suspension cells, 
in addition to a multiple array of culture devices are used. Therefore, the harvesting protocol is likely 
to be process-specific and require optimisation in each instance. In most instances, the process is likely 
to involve the use of an animal-free recombinant enzymatic dissociation reagent such as recombinant 
trypsin and some physical force exerted through an increase in impeller agitation, bioreactor rotation 
or increased flow rates depending on the culture vessel employed. For example, the harvesting of cells 
using anchorage-dependent hMSCs cultured in stirred-tank bioreactors on microcarriers requires a 
combination of enzymatic dissociation and mechanical force (through impeller agitation) to aid in the 
successful detachment of cells from the microcarriers in situ [7].  
This procedure has been employed successfully for a range of anchorage-dependent cell types in a 
range of bioreactor systems and in all cases (Figure 1), importantly, demonstrated retention of the 
CQAs [8] despite concerns that the increase in agitation will result in cell-damaging shear forces. This 
harvesting method has demonstrated that it is possible to increase impeller agitation. This aids in the 
rate of cell detachment, whilst ensuring that the Kolmogorov scale remains greater than the size of 
the cell once it has been detached and therefore unlikely to cause cell damage. Such an approach led 
to > 95% harvesting efficiency with the cells demonstrating retention of CQAs, despite a five-fold 
increase in the impeller agitation (compared to the original culture agitation) and a Kolmogorov scale 
of ~ 30 µm, larger than the average diameter of the cells (~15 µm) [7]. This in situ detachment 
procedure should be scalable to larger, industrial-scale bioreactors having been established on well-
understood theoretical mixing principles. Moreover, given the detachment procedure is undertaken 
in situ, it eliminates the need for an additional processing step outside of the culture vessel, reduces 
contamination risk and decreases time between process steps. 
Although the procedure is likely to involve the use of a recombinant dissociation reagent, the harvest 
of a hollow-fibre or packed-bed bioreactor culture is likely to be different and may involve extended 
contact with the dissociation reagent, increased flow rates, and/or rotation of the culture vessel. In all 
instances of the harvesting procedure, it is important, particularly where mechanical forces are used 
to dissociate cells, that no additional debris or particulates arise due to the microcarrier/cell-substrate 
damage. Such an outcome would result in additional burden on the DSP operations to remove such 
particulates. Some groups have demonstrated successful culture of cells on biodegradable 
microcarriers [9] to overcome this concern, yet this may still pose a concern for final formulation and 
patient administration.  
Advances in biomaterial formulation have facilitated the development of alternative approaches for 
cell harvesting with multiple studies demonstrating the potential to remove the need for enzymatic 
dissociation reagents and mechanical agitation to facilitate successful harvest. Such approaches 
include the use of environmentally responsive polymers to coat microcarriers which enable both the 
culture of anchorage-dependent cells and the subsequent detachment of the cells through a change 
in the culture temperature and/or pH [10, 11]. Although promising, there is a concern that non-
enzymatic methods for cell dissociation results in the formation of cell sheets rather than a single-cell 
suspension; this may be inappropriate for applications that require intravenous administration.  
Volume reduction, wash and formulation  
CGTs to date use swing-bucket rotor centrifugation for cell washing and concentration. A biological 
safety cabinet usually is needed for the subsequent resuspension step, which involves discarding spent 
medium and resuspending in a suitable buffer. This process may be repeated multiple times to ensure 
the complete removal of any unwanted reagents and/or particles. However, centrifugation has proven 
to be a difﬁcult step to automate while maintaining sterility [1] and can pose a problem to achieve the 
required cell numbers for the manufacture of highly concentrated CGTs [12]. Alternatives to swing-
bucket rotor centrifugation, include continuous counterflow centrifugation systems and filtration 
systems which can be more amenable to large-scale, contained and automated operations [6]. 
Counterflow centrifugation systems, such as kSep® (KBI Biopharma) and Elutra cell separation system 
(Terumo BCT), can keep the cells in suspension whilst washing them, clearing out residuals from the 
supernatant and exchanging the buffer. kSep® in particular can be fully automated and contained, 
uses a disposable flow path, is scalable from 0.1 L to >1000 L and can achieve high cell recoveries 
(>80%) and high cell viabilities (>90%). The capital investment needed, together with the cost of 
disposables, demands careful consideration when carrying out process development [6]. 
Tangential flow filtration (TFF) offers an alternative that can also be scaled, automated, fully contained 
and, generally, involves a lower capital investment and disposables costs, which may make it more 
amenable to process development activities [6]. For instance, for the anchorage-dependent cells, after 
the cells are enzymatically dissociated into a single-cell suspension (whether that is detachment from 
microcarriers, culture surfaces, colonies or embryoid bodies), these are generally quenched with 
culture media to preserve cell health by preventing the enzyme from further digesting cell 
components. More specifically, for the hMSC microcarrier-based expansion outlined previously, cell 
detachment from the microcarrier is only one aspect of the harvesting procedure. Assuming the 
microcarriers are not biodegradable and not part of the final product formulation, the next DSP step 
is likely to be the separation of cells from microcarriers by size exclusion techniques. For example, 
dead end filtration using a vacuum as a driving force was employed in the aforementioned hMSCs 
studies [7, 8]. However, this technique, although suitable for the purposes of the study, is not a 
scalable technique like TFF. Other groups have used TFF and expanded bed chromatography (EBC) as 
continuous, integrated alternative techniques for the improved washing and concentration of hMSCs 
[13, 14]. Cunha and colleagues showed high protein clearance (98%), high recovery of viable hMSCs 
(70%) with no impact on cell viability (95%) or other CQAs (morphology, immunophenotyped, 
proliferation, adhesion capacity and multipotent differentiation potential) [13, 14]. Furthermore, 
these studies show shorter processing times when using continuous filtration techniques as opposed 
to discountinuous operations. 
Another recent technique that is showing promise for the DSP of CGTs is acoustic filtration [15, 16]. 
Acoustic filtration uses standing waves to capture, separate and concentrate particles in a fluid 
without having a physical barrier (membrane or filter) like traditional filtration systems. It is therefore 
considered suitable for shear-sensitive cell lines and potentially allows for higher throughput, together 
with less clogging issues than traditional membrane based systems, extending the lifetime of the 
disposables.  
Addressing the DSP challenges 
Due to the relative infancy of the CGT DSP space, a large proportion of the research and development 
activity needs to focus on effective process development and understanding of the critical process 
parameters (CPPs) at the small scale. The development of bench-scale technologies which better 
mimic the full scale will be paramount to the rapid development of robust DSP processes and allow 
cost-effective screening of the susceptibility of cell lines to operating conditions for CGTs [17]. To date, 
some efforts have focused on the development of ultra scale-down (USD) tools to mimic various large 
scale operations such as continuous centrifugation [18] dead end filtration [19, 20] and membrane 
separation [21, 22] (Table 1). USD devices allow the investigation of several manufacturing 
hydrodynamic environments [21] and geometries [23] with little material, increasing the throughput 
of the experimental phase in a cost-effective and time-efﬁcient manner and ultimately, expediting 
process development of DSP operations.  
Delivering effective DSP technologies and robust processes with the capacity to target specificity and 
throughput is required to ensure that advances in upstream processing are maximised. Effective scale-
down models, adequately characterised, may facilitate a thorough understanding of the CPPs and 
expedite process optimisation and parameter screening studies in a cost-effective and timely manner. 
Moreover, further process understanding and knowledge of the product’s CQAs will be key to develop 
effective and suitable DSP solutions with the capacity to scale and quality requirements of CGT 
products. 
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Figures/Tables: 
 
Figure 1: Phase-contrast image of single hMSCs in suspension following detachment from 
microcarriers 
 
 
DSP Unit Operation Reference 
Continuous centrifugation Bocyhyn et al. 2001 [24] 
Hutchinson et al. 2006 [18] 
Batch centrifugation Delahaye et al. 2015 [25] 
Hutchinson et al. 2006 [18] 
McCoy et al. 2009 [26] 
Chromatography Titchener-Hooker et al. 2008 [27] 
Hutchinson et al. 2006 [18] 
Membrane separation (TFF) Masri et al. 2017 [21] 
Ma et al. 2010 [22] 
Depth filtration Jackson et al. 2006 [19]  
Lau et al. 2013 [20] 
Fill and finish (capillaries) Acosta-Martinez et al. 2010 [23] 
 
Table 1: Overview of ultra scale-down tools reported in literature as predictive tools for several 
different large-scale downstream processing steps and/or processing parameters 
